Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-3424 vs regorafenib in AKR1C3-high advanced hepatocellular carcinoma after immune checkpoint inhibitor therapy
CTR20254704Phase 2Active
- Sponsor
- Accendatech
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of odafosfamide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Accendatech. Primary endpoint: 9-month overall survival rate. Started Jan 2026; status: active.
02
Drugs
odafosfamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254704.